MCL-1 as a potent target for cancer: Recent advancements, structural insights and SAR studies

Vishakha Sharma and Ankush Kumar

Bioorganic Chemistry, 2025, 156, 108211
DOI: 10.1016/j.bioorg.2025.108211

The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN–GIL hybrid single-molecule inhibitors

Christopher C. Goodis, Christian Eberly, Alexandria M. Chan, MinJung Kim, Brandon D. Lowe, Curt I. Civin and Steven Fletcher

European Journal of Medicinal Chemistry, 2025, 285, 117190
DOI: 10.1016/j.ejmech.2024.117190

A new Nickel Complex of Lysine on Mesoporous KIT-6 as a Recoverable and Selective Catalyst in the Synthesis of Tetrazoles

Elham Mohseni, Arash Ghorbani‑Choghamarani, Bahman Tahmasbi, Masoomeh Norouzi and Manzar Akbari

J Inorg Organomet Polym, 2025, 35, 4432
DOI: 10.1007/s10904-024-03532-3

2-azolylindoles: synthesis and evaluation of their potential as metallo-β-lactamase inhibitors

Pavel Tiuleanu, Ivan V. Ivanov, Kirill V. Rychev, Natalia E. Grammatikova, Irina P. Andreeva, Vitaly G. Grigorenko, Alexander M. Scherbakov, Alexey M. Egorov and Andrey E. Shchekotikhin

Med Chem Res, 2025, 34, 1714
DOI: 10.1007/s00044-025-03436-y